Market: NMS |
Currency: USD
Address: 3957 Point Eden Way
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
📈 Pulse Biosciences, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$30.00
-
Upside/Downside from Analyst Target:
98.81%
-
Broker Call:
4
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
2026-05-08
-
EPS Estimate:
-0.22
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Pulse Biosciences, Inc.
| Date | Reported EPS |
|---|
| 2026-05-07 (estimated upcoming) | - |
| 2026-02-19 | -0.18 |
| 2025-11-05 | -0.29 |
| 2025-08-12 | -0.28 |
| 2024-05-07 | -0.18 |
| 2023-08-10 | -0.22 |
| 2023-05-11 | -0.26 |
| 2023-03-30 | -0.25 |
| 2022-11-10 | -0.49 |
| 2022-08-10 | -0.44 |
| 2022-05-11 | -0.58 |
| 2022-03-31 | -0.52 |
| 2021-11-15 | -0.48 |
| 2021-08-09 | -0.48 |
| 2021-05-10 | -0.44 |
| 2021-02-22 | -0.54 |
| 2020-11-09 | -0.51 |
| 2020-08-10 | -0.53 |
| 2020-05-11 | -0.57 |
| 2020-03-16 | -0.66 |
| 2019-11-07 | -0.57 |
| 2019-08-08 | -0.55 |
| 2019-04-30 | -0.49 |
📰 Related News & Research
-
Pulse Biosciences, Inc. 8-K SEC Filing March 23, 2026 – Company Information, NASDAQ Listing, and Key Details
March 28, 2026
Pulse Biosciences, Inc. Announces Significant Restricted Sto...
-
Pulse Biosciences Announces Organizational Realignment to Accelerate Cardiac Catheter Program After Exceptional AFib Clinical Results
March 17, 2026
Pulse Biosciences Announces Organizational Realignment to Ac...
-
Pulse Biosciences Announces Long-Term Clinical Data for nPulse Vybrance Percutaneous Electrode System in Benign Thyroid Nodule Ablation 71314
March 9, 2026
Pulse Biosciences, Inc. Announces Positive Clinical Data for...
-
Pulse Biosciences Investor Presentation March 2026 – Company Overview, Financials, and Strategic Updates
March 4, 2026
Pulse Biosciences, Inc. Releases Updated Investor Presentati...
-
Pulse Biosciences, Inc. Form 8-K Filing Details (Feb. 27, 2026) – Company, Stock, and Regulatory Information
February 28, 2026
Pulse Biosciences, Inc. 8-K Filing: Executive Resignation An...
-
Pulse Biosciences, Inc. 2024 Financial Results and SEC Filing Details
February 20, 2026
Pulse Biosciences Reports Q4 and Full Year 2025 Results: Bus...
🔍 View more Reports